 After months of delays, the FDA has approved a new treatment designed to slow the progression of Alzheimer's. Chief Medical Correspondent, Dr. John LaPook. Denonimab is the second drug available for Alzheimer's patients with early symptoms. It will be sold under the brand name Kesunla, and it slowed cognitive decline overall by about 22% over 18 months. Complications can include bleeding in the brain.